Cargando…

Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study

BACKGROUND: Antireflux mucosectomy, a new endoscopic treatment for gastroesophageal reflux disease, consists of endoscopic mucosal resection at the esophagogastric junction. This study aim was to evaluate the medium-term efficacy of the antireflux mucosectomy technique for patients with severe gastr...

Descripción completa

Detalles Bibliográficos
Autores principales: Laquière, Arthur, Trottier-Tellier, Felix, Urena-Campos, Romina, Lienne, Pascal, Lecomte, Laurence, Katsogiannou, Maria, Penaranda, Guillaume, Boustière, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885295/
https://www.ncbi.nlm.nih.gov/pubmed/35237316
http://dx.doi.org/10.1155/2022/1606944
_version_ 1784660381954736128
author Laquière, Arthur
Trottier-Tellier, Felix
Urena-Campos, Romina
Lienne, Pascal
Lecomte, Laurence
Katsogiannou, Maria
Penaranda, Guillaume
Boustière, Christian
author_facet Laquière, Arthur
Trottier-Tellier, Felix
Urena-Campos, Romina
Lienne, Pascal
Lecomte, Laurence
Katsogiannou, Maria
Penaranda, Guillaume
Boustière, Christian
author_sort Laquière, Arthur
collection PubMed
description BACKGROUND: Antireflux mucosectomy, a new endoscopic treatment for gastroesophageal reflux disease, consists of endoscopic mucosal resection at the esophagogastric junction. This study aim was to evaluate the medium-term efficacy of the antireflux mucosectomy technique for patients with severe gastroesophageal reflux disease symptoms (proton pump inhibitor treatment-dependent or proton pump inhibitor treatment-resistant gastroesophageal reflux disease). METHODS: Between January 2017 and June 2018, 13 patients with severe gastroesophageal reflux disease without hiatal hernia, with positive pH reflux, were included in this monocentric prospective pilot study. The primary outcome was clinical success, defined by improvement evaluated by the Gastroesophageal Reflux Disease Health Related Quality of Life Questionnaire at 24 months. Secondary outcomes were technical success, decreased use of proton pump inhibitors, patient satisfaction, and adverse events. RESULTS: Thirteen patients [females = 8 (62%)], mean age 59 (range, 54-68), were included. The antireflux mucosectomy procedure had technical success in all patients. At 24 months, for 11 patients, gastroesophageal reflux disease symptoms were significantly improved, and mean gastroesophageal reflux disease score decreased from 33 (range, 26-42) to 3 (range, 0-7) (p = 0.001). Ninety-one percent (n = 10) of patients had a lower proton pump inhibitor intake at 24 months. One patient had 3 endoscopic balloon dilatations for EGJ stenosis, two patients had melena ten days after procedure, and seven patients had thoracic or abdominal pain. Patient's satisfaction at 24 months was 81%. CONCLUSIONS: In patients with severe gastroesophageal reflux disease, despite occurrence of several short-term adverse events, antireflux mucosectomy seemed effective in improving gastroesophageal reflux disease symptoms at 24 months. This trial is registered with ClinicalTrials: NCT03357809.
format Online
Article
Text
id pubmed-8885295
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88852952022-03-01 Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study Laquière, Arthur Trottier-Tellier, Felix Urena-Campos, Romina Lienne, Pascal Lecomte, Laurence Katsogiannou, Maria Penaranda, Guillaume Boustière, Christian Gastroenterol Res Pract Research Article BACKGROUND: Antireflux mucosectomy, a new endoscopic treatment for gastroesophageal reflux disease, consists of endoscopic mucosal resection at the esophagogastric junction. This study aim was to evaluate the medium-term efficacy of the antireflux mucosectomy technique for patients with severe gastroesophageal reflux disease symptoms (proton pump inhibitor treatment-dependent or proton pump inhibitor treatment-resistant gastroesophageal reflux disease). METHODS: Between January 2017 and June 2018, 13 patients with severe gastroesophageal reflux disease without hiatal hernia, with positive pH reflux, were included in this monocentric prospective pilot study. The primary outcome was clinical success, defined by improvement evaluated by the Gastroesophageal Reflux Disease Health Related Quality of Life Questionnaire at 24 months. Secondary outcomes were technical success, decreased use of proton pump inhibitors, patient satisfaction, and adverse events. RESULTS: Thirteen patients [females = 8 (62%)], mean age 59 (range, 54-68), were included. The antireflux mucosectomy procedure had technical success in all patients. At 24 months, for 11 patients, gastroesophageal reflux disease symptoms were significantly improved, and mean gastroesophageal reflux disease score decreased from 33 (range, 26-42) to 3 (range, 0-7) (p = 0.001). Ninety-one percent (n = 10) of patients had a lower proton pump inhibitor intake at 24 months. One patient had 3 endoscopic balloon dilatations for EGJ stenosis, two patients had melena ten days after procedure, and seven patients had thoracic or abdominal pain. Patient's satisfaction at 24 months was 81%. CONCLUSIONS: In patients with severe gastroesophageal reflux disease, despite occurrence of several short-term adverse events, antireflux mucosectomy seemed effective in improving gastroesophageal reflux disease symptoms at 24 months. This trial is registered with ClinicalTrials: NCT03357809. Hindawi 2022-02-21 /pmc/articles/PMC8885295/ /pubmed/35237316 http://dx.doi.org/10.1155/2022/1606944 Text en Copyright © 2022 Arthur Laquière et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Laquière, Arthur
Trottier-Tellier, Felix
Urena-Campos, Romina
Lienne, Pascal
Lecomte, Laurence
Katsogiannou, Maria
Penaranda, Guillaume
Boustière, Christian
Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study
title Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study
title_full Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study
title_fullStr Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study
title_full_unstemmed Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study
title_short Evaluation of Antireflux Mucosectomy for Severe Gastroesophageal Reflux Disease: Medium-Term Results of a Pilot Study
title_sort evaluation of antireflux mucosectomy for severe gastroesophageal reflux disease: medium-term results of a pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885295/
https://www.ncbi.nlm.nih.gov/pubmed/35237316
http://dx.doi.org/10.1155/2022/1606944
work_keys_str_mv AT laquierearthur evaluationofantirefluxmucosectomyforseveregastroesophagealrefluxdiseasemediumtermresultsofapilotstudy
AT trottiertellierfelix evaluationofantirefluxmucosectomyforseveregastroesophagealrefluxdiseasemediumtermresultsofapilotstudy
AT urenacamposromina evaluationofantirefluxmucosectomyforseveregastroesophagealrefluxdiseasemediumtermresultsofapilotstudy
AT liennepascal evaluationofantirefluxmucosectomyforseveregastroesophagealrefluxdiseasemediumtermresultsofapilotstudy
AT lecomtelaurence evaluationofantirefluxmucosectomyforseveregastroesophagealrefluxdiseasemediumtermresultsofapilotstudy
AT katsogiannoumaria evaluationofantirefluxmucosectomyforseveregastroesophagealrefluxdiseasemediumtermresultsofapilotstudy
AT penarandaguillaume evaluationofantirefluxmucosectomyforseveregastroesophagealrefluxdiseasemediumtermresultsofapilotstudy
AT boustierechristian evaluationofantirefluxmucosectomyforseveregastroesophagealrefluxdiseasemediumtermresultsofapilotstudy